Results 131 to 140 of about 72,473 (300)
Movement Disorders, EarlyView.Abstract Background The activation of the NOD‐, LRR‐ and pyrin domain‐containing protein 3 (NLRP3) inflammasome and associated immune dysregulation is one of the key pathological processes preceding and accompanying α‐synuclein pathology, neuronal damage, and cell death in Parkinson's disease (PD).
Alina‐Măriuca Marinescu +9 more
wiley +1 more source
GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson\u27s Disease. [PDF]
, 2019 While GM1 may interact with α-synuclein in vitro to inhibit aggregation, the ability of GM1 to protect against α-synuclein toxicity in vivo has not been investigated.
Aras, Radha +5 more
core +1 more source
EBioMedicineSummary: Background: Idiopathic rapid eye movement (REM) sleep behaviour disorder (IRBD) represents the prodromal stage of Lewy body disorders (Parkinson's disease (PD) and dementia with Lewy bodies (DLB)) which are linked to variations in circulating ...
Margalida Puigròs +12 more
doaj +1 more source
Electron microscopy analysis of alpha-synuclein and LRRK2 transgenic C. elegans [PDF]
, 2013 Thesis (M.A.)--Boston UniversityMutations in alpha-synuclein and leucine-rich repeat kinase 2 (LRRK2) have been implicated in the cause of Parkinson’s disease (PD).
Nguyen, Andrew Huy
core +1 more source
Beyond Pathology: α‐Synuclein Homeostasis and Three Principles to Guide Research
Movement Disorders Clinical Practice, EarlyView.
Alberto J. Espay, Andrew J. Lees
wiley +1 more source
Bipolar Disorder as a Long‐Term Risk Factor for Parkinson's Disease: A Nationwide Case–Control Study
Movement Disorders, EarlyView.Abstract Background Previous studies suggest an association between bipolar disorder (BD) and an increased risk of Parkinson's disease (PD), but the long‐term temporal relationship remains unclear. Particularly, it is unclear whether the risk of PD is influenced by the duration since BD diagnosis.
Elina Jaakkola +5 more
wiley +1 more source
Nuclear Alpha‐Synuclein: Mechanisms and Implications for Synucleinopathies
Movement Disorders, EarlyView.Abstract Alpha‐synuclein (aSyn), historically studied for its synaptic functions and central role in Lewy body pathology, is emerging as a protein with significant nuclear activities relevant to Parkinson's disease (PD) and related synucleinopathies. Recent advances reveal that aSyn dynamically localizes to neuronal nuclei in both health and disease ...
Tiago Fleming Outeiro, David J. Koss
wiley +1 more source
Focused Ultrasound for the Treatment of Circuit and Molecular Pathology in Parkinson's Disease
Movement Disorders, EarlyView.Abstract Focused ultrasound is rapidly emerging as a novel technology for the development of symptomatic therapies and supporting disease‐modifying treatments for Parkinson's disease (PD). At the forefront of this development is thermoablation using high‐intensity focused ultrasound, an incisionless treatment that has been extensively tested in ...
Rikke Hahn Kofoed +7 more
wiley +1 more source
Nature CommunicationsLewy body (LB) diseases, characterized by the aggregation of misfolded α-synuclein proteins, exhibit notable clinical heterogeneity. This may be due to variations in accumulation patterns of LB neuropathology.
Sophie E. Mastenbroek +17 more
doaj +1 more source